Surrozen, Inc. has sharpened its business strategy exclusively towards ophthalmology, leveraging its pioneering Wnt pathway modulation platform. Despite robust financing efforts, including a $175 million private placement in 2025 and over $89 million in year-end cash, the company recorded a significant net loss of $242 million for FY2025, reflecting intensified R&D spending and pipeline advancements. Operationally, Surrozen made progress with key programs such as SZN-8141 while discontinuing non-core assets like SZN-043. Near-term growth prospects hinge on clinical trial outcomes and sustained capital raises via its sales agreement offering up to $50 million.